Financings In Brief
This article was originally published in The Gray Sheet
Cancer Genetics plans initial public offering. Mitralign raises $35 million for valve repair device. More financings.
You may also be interested in...
Maquet acquires LAAx. OrbusNeich says it called the cops on Boston Scientific. More news
Sonitus’ SoundBite gains second FDA OK